View all adult cancer types
View all pediatric cancer types
Susan F. Smith Center for Women's Cancers
Gynecologic CancerBlood CancersCancer Genetics and PreventionCutaneous (Skin) CancerGastrointestinal CancerGenitourinary CancerHead and Neck CancerHematologyMelanomaNeuro-OncologySarcomaStem Cell TransplantThoracic (Lung) Cancer
Blood DisordersBrain TumorsHematologic MalignanciesSolid TumorsStem Cell Transplant
Researchers from the Susan F. Smith Center for Women’s Cancers at Dana-Farber report that for some women with recurrent ovarian cancer, a new drug combination has been found to stall the progression of the disease.
The American Society of Clinical Oncology (ASCO) today issued a new clinical practice guideline on chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer. The guideline provides detailed, evidenced-based information on the efficacy and side effects of various therapies.
The Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO), has awarded Dana-Farber Cancer Institute a three-year certification for outpatient hematology-oncology practices that meet its highest standards for quality cancer care.
Children born with so-called “bubble boy” disease have the best chance of survival if they undergo a hematopoietic stem cell transplant as soon after birth as possible, according to a detailed analysis of 10 years published in the New England Journal of Medicine. The researchers say the findings argue for expanding newborn screening for the life-threatening immune disorder.
A clinical trial led by Dr. Ursula Matulonis and Dr. Joyce Liu showed a two-drug combination can signficantly improve benefit for women with ovarian cancer that has recurred after initial treatment.
Dr. Harold Burstein commented on a study that found there was no evidence that surgery lowered the risk of death compared to more conservative lumpectomy and radiation.
Shannon Harrington, PhD, participated in a study showing a patient's race and ethnicity dramatically influenced their preferences about the care they receive at the end of their lives.
Dr. William Kaelin commented on the cancer-stem-cell model, and the possibility of controlling cancer without killing it.
Rafael Irizarry, PhD, co-led a new study investigating all stages and types of cancers that appear to share a telltale signature of widespread changes to the epigenome.
Former Red Sox pitcher and Dana-Farber patient Curt Schilling announced he will return to ESPN as a studio analyst after he took a leave of absence following his cancer diagnosis.
Former Dana-Farber/Boston Children’s Cancer and Blood Disorders Center patient Kate Franklin spent the summer interning in the lab of Dr. Loren Walensky, who treated her for leukemia when she was a child.
Tai Chi for Optimal Health
3:00 PM - 4:30 PM
Smith Room, 330, Stoneman Patient Services Suite
An internal Chinese martial art practiced for both defense training and health benefits. Learn sitting and standing techniques as well as slow moving meditation. Open to patients and family members. Please register at 617-632-3322.
4:30 PM - 6:00 PM
Smith Room 330, Stoneman Patient Services Suite
Fine tune your mind/body skills and create balance among them. Open to patients and family members. Please register at 617-632-3322.
Melanoma Support Group(6)
5:30 PM - 7:00 PM
This group offers you can opportunity to develop a peer network of shared understanding and support in a setting where you can discuss;
Pre-registration is required: To register or for more info: Contact Nancy Bailey at 617-632-3599
Deaconess Medical Center. Call Frank McCaffrey 617 667-3525
Patient referral information, clinical resources and more.
For adults:877-442-3324For children:888-733-4662Or complete the online form.
Search current cancer clinical trials at Dana-Farber.
There are many ways to support Dana-Farber and the Jimmy Fund.
More ways to helpGiving Catalog
Top-ranked cancer center in New England for adults — #1 in the nation for children's cancer
Insight features the latest in cancer care and research news from Dana-Farber.Read the blog
Stay current on the latest news by signing up for Spotlight, our email newsletter.View current issueSubscribe now
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: